Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis

References

• FriedmanDSO’ColmainBJMuñozBEye Diseases Prevalence Research GroupPrevalence of age-related macular degeneration in the United StatesArch Ophthalmol2004122456457215078675
   PubMed Web of Science ®Google Scholar
• KlaverCCWolfsRCVingerlingJRHofmanAde JongPTAge-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam studyArch Ophthalmol199811656536589596502
   PubMed Web of Science ®Google Scholar
• WangJJForanSMitchellPAge-specific prevalence and causes of bilateral and unilateral visual impairment in older Australians: the Blue Mountains Eye StudyClin Exp Ophthalmol200028426827311021555
   PubMed Web of Science ®Google Scholar
• WongWLSuXLiXGlobal prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysisLancet Glob Health201422e106e11625104651
   PubMed Web of Science ®Google Scholar
• ResnikoffSPascoliniDEtya’aleDGlobal data on visual impairment in the year 2002Bull World Health Organ2004821184485115640920
   PubMed Web of Science ®Google Scholar
• GehrsKMAndersonDHJohnsonLVHagemanGSAge-related macular degeneration – emerging pathogenetic and therapeutic conceptsAnn Med200638745047117101537
   PubMed Web of Science ®Google Scholar
• BresslerNMAge-related macular degeneration is the leading cause of blindnessJAMA2004291151900190115108691
   PubMedGoogle Scholar
• EmersonMVLauerAKCurrent and emerging therapies for the treatment of age-related macular degenerationClin Ophthalmol20082237738819668729
   PubMedGoogle Scholar
• U.S. National Institutes of HealthCurrent studies: dry macular degeneration Available from: https://clinicaltrials.gov/ct2/results?term=dry+macular+degeneration&Search=SearchAccessed July 7, 2016
   Google Scholar
• WangHHartnettMERegulation of signaling events involved in the pathophysiology of neovascular AMDMol Vis20162218920227013848
   PubMed Web of Science ®Google Scholar
• WangLLeeAYWiggJPPeshavariyaHLiuPZhangHmiR-126 regulation of angiogenesis in age-related macular degeneration in CNV mouse modelInt J Mol Sci2016176
   Web of Science ®Google Scholar
• JagerRDMielerWFMillerJWAge-related macular degenerationN Engl J Med2008358242606261718550876
   PubMed Web of Science ®Google Scholar
• U.S. Food & Drug AdministrationFDA approves new biologic treatment for wet age-related macular degeneration2006 Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108685.htmAccessed July 18, 2016
   Google Scholar
• US Food & Drug AdministrationFDA approves Eylea for eye disorder in older people2011 Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm280601.htmAccessed July 18, 2016
   Google Scholar
• HeierJSBrownDMChongVVIEW 1 and VIEW 2 Study GroupsIntravitreal aflibercept (VEGF trap-eye) in wet age-related macular degenerationOphthalmology2012119122537254823084240
   PubMed Web of Science ®Google Scholar
• EhlkenCJungmannSBöhringerDAgostiniHTJunkerBPielenASwitch of anti-VEGF agents is an option for nonresponders in the treatment of AMDEye (Lond)201428553854524722504
   PubMed Web of Science ®Google Scholar
• BinderSLoss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance?Br J Ophthalmol20129611222157632
   PubMed Web of Science ®Google Scholar
• BroadheadGKHongTChangAATreating the untreatable patient: current options for the management of treatment-resistant neovascular age-related macular degenerationActa Ophthalmol201492871372324925048
   PubMed Web of Science ®Google Scholar
• HigginsJPThompsonSGDeeksJJAltmanDGMeasuring inconsistency in meta-analysesBMJ2003327741455756012958120
   PubMed Web of Science ®Google Scholar
• DownsSHBlackNThe feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventionsJ Epidemiol Community Health19985263773849764259
   PubMed Web of Science ®Google Scholar
• HigginsJPThompsonSGQuantifying heterogeneity in a meta-analysisStat Med200221111539155812111919
   PubMed Web of Science ®Google Scholar
• BroadheadGKHongTZhuMResponse of pigment epithelial detachments to intravitreal aflibercept among patients with treatment-resistant neovascular age-related macular degenerationRetina201535597598125627086
   PubMed Web of Science ®Google Scholar
• ChangAABroadheadGKHongTIntravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration: 12-month safety and efficacy outcomesOphthalmic Res2015552849026637166
   PubMed Web of Science ®Google Scholar
• ChangAALiHBroadheadGKIntravitreal aflibercept for treatment-resistant neovascular age-related macular degenerationOphthalmology2014121118819224144450
   PubMed Web of Science ®Google Scholar
• AghdamKAPielenAFrammeCJunkerBVisual and anatomic outcomes after conversion to aflibercept in neovascular age-related macular degeneration: 12-month resultsEur J Ophthalmol201626547347826868007
   PubMed Web of Science ®Google Scholar
• GrewalDSGillMKSarezkyDLyonATMirzaRGVisual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month resultsEye (Lond)201428789589924833178
   PubMed Web of Science ®Google Scholar
• MantelIGianniouCDiraniAConversion to aflibercept therapy versus continuing with ranibizumab therapy for neovascular age-related macular degeneration dependent on monthly ranibizumab treatmentRetina2016361535826166797
   PubMed Web of Science ®Google Scholar
• SaraoVParravanoMVerittiDAriasLVaranoMLanzettaPIntra-vitreal aflibercept for chorioidal neovascularization due to age-related macular degeneration unresponsive to ranibizumab therapyRetina201636477077726398691
   PubMed Web of Science ®Google Scholar
• WykoffCCBrownDMMaldonadoMECroftDEAflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial)Br J Ophthalmol201498795195524518078
   PubMed Web of Science ®Google Scholar
• ArcinueCAMaFBarteselliGSharpstenLGomezMLFreemanWROne-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degenerationAm J Ophthalmol20151593426436.e225461263
   PubMed Web of Science ®Google Scholar
• BarthelmesDCampainANguyenPFight Retinal Blindness! Project InvestigatorsEffects of switching from ranibizumab to afliber-cept in eyes with exudative age-related macular degenerationBr J Ophthalmol2016100121640164526994110
   PubMed Web of Science ®Google Scholar
• ChanCKJainASaddaSVarshneyNOptical coherence tomographic and visual results at 6 months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis)Trans Am Ophthalmol Soc201411216019825646034
   PubMedGoogle Scholar
• de MassougnesSDiraniAAmbresinADecugisDMarchionnoLMantelIPigment epithelial detachment response to aflibercept in neovascular age-related macular degeneration refractory to ranibizumab: time course and drug effectsRetina201636588188827115852
   PubMed Web of Science ®Google Scholar
• EadieJAGottliebJLIpMSResponse to aflibercept in patients with persistent exudation despite prior treatment with bevacizumab or ranibizumab for age-related macular degenerationOphthalmic Surg Lasers Imaging Retina201445539439725230402
   PubMed Web of Science ®Google Scholar
• GharbiyaMIannettiLParisiFDe VicoUMungoMLMarencoMVisual and anatomical outcomes of intravitreal aflibercept for treatment-resistant neovascular age-related macular degenerationBioMed Res Int2014201427375424895562
   PubMed Web of Science ®Google Scholar
• HallLBZebardastNHuangJJAdelmanRAAflibercept in the treatment of neovascular age-related macular degeneration in previously treated patientsJ Ocul Pharmacol Ther201430434635224552305
   PubMed Web of Science ®Google Scholar
• Kanesa-ThasanAGrewalDSGillMKLyonATMirzaRGQuantification of change in pigment epithelial detachment volume and morphology after transition to intravitreal aflibercept in eyes with recalcitrant neovascular AMD: 18-month resultsOphthalmic Surg Lasers Imaging Retina201546663864126114844
   PubMed Web of Science ®Google Scholar
• KumarNMarsigliaMMrejenSVisual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degenerationRetina20133381605161223549101
   PubMed Web of Science ®Google Scholar
• NarayanDSMueckeJIntravitreal aflibercept treatment in eyes with exudative age-related macular degeneration following prior treatment with intravitreal ranibizumabIndian J Ophthalmol2015631183283626669334
   PubMed Web of Science ®Google Scholar
• ThorellMRNunesRPChenGWResponse to aflibercept after frequent re-treatment with bevacizumab or ranibizumab in eyes with neovascular AMDOphthalmic Surg Lasers Imaging Retina201445652653325423632
   PubMed Web of Science ®Google Scholar
• ChoHShahCPWeberMHeierJSAflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumabBr J Ophthalmol20139781032103523766432
   PubMed Web of Science ®Google Scholar
• BakallBFolkJCBoldtHCAflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumabAm J Ophthalmol201315611522.e123706500
   PubMed Web of Science ®Google Scholar
• ChatziralliINicholsonLVrizidouEPredictors of outcome in patients with neovascular age-related macular degeneration switched from ranibizumab to 8-weekly afliberceptOphthalmology201612381762177027289179
   PubMed Web of Science ®Google Scholar
• Pinheiro-CostaJCostaJMBeatoJNSwitch to aflibercept in the treatment of neovascular AMD: one-year results in clinical practiceOphthalmologica20152333–415516125896317
   PubMed Web of Science ®Google Scholar
• GerdingHFunctional and anatomic efficacy of a conversion to aflibercept in eyes with age-related macular degeneration after long-term ranibizumab treatmentKlin Monbl Augenheilkd2015232456056325902122
   PubMed Web of Science ®Google Scholar
• HaririADinizBFouLVLamLANittalaMGSaddaSRQuantitative OCT subanalysis of eyes with choroidal neovascularization switched from multiple injections of bevacizumab or ranibizumab to intravitreal afliberceptOphthalmic Surg Lasers Imaging Retina201546219520025707044
   PubMed Web of Science ®Google Scholar
• HeLSilvaRAAyoubNMoshfeghiDMLengTExperience with aflibercept for the treatment of neovascular age-related macular degenerationOphthalmic Surg Lasers Imaging Retina201546554254926057757
   PubMed Web of Science ®Google Scholar
• MajorJCJrWykoffCCCroftDEAflibercept for pigment epithelial detachment for previously treated neovascular age-related macular degenerationCan J Ophthalmol201550537337726455973
   PubMed Web of Science ®Google Scholar
• RicciFParravanoMRegineFAflibercept in persistent neovascular AMD: comparison of different treatment strategies in switching therapyEye (Lond)20163081077108327229701
   PubMed Web of Science ®Google Scholar
• FrancisPJThe influence of genetics on response to treatment with ranibizumab (Lucentis) for age-related macular degeneration: the Lucentis Genotype Study (an American Ophthalmological Society thesis)Trans Am Ophthalmol Soc201110911515622253485
   PubMedGoogle Scholar
• de Oliveira DiasJRRodriguesEBMaiaMMagalhãesOJrPenhaFMFarahMECytokines in neovascular age-related macular degeneration: fundamentals of targeted combination therapyBr J Ophthalmol201195121631163721546514
   PubMed Web of Science ®Google Scholar
• KrebsIGlittenbergCAnsari-ShahrezaeiSHagenSSteinerIBinderSNon-responders to treatment with antagonists of vascular endothelial growth factor in age-related macular degenerationBr J Ophthalmol201397111443144623966368
   PubMed Web of Science ®Google Scholar
• MoutrayTAlarbiMMahonGStevensonMChakravarthyURelationships between clinical measures of visual function, fluorescein angiographic and optical coherence tomography features in patients with subfoveal choroidal neovascularisationBr J Ophthalmol200892336136418303157
   PubMed Web of Science ®Google Scholar
• MartinDFMaguireMGFineSLComparison of Age-related Macular Degeneration Treatments Trials (CATT) Research GroupRanibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year resultsOphthalmology201211971388139822555112
   PubMed Web of Science ®Google Scholar
• GrunwaldJEDanielEHuangJCATT Research GroupRisk of geographic atrophy in the comparison of age-related macular degeneration treatments trialsOphthalmology2014121115016124084496
   PubMed Web of Science ®Google Scholar
• ChengSLengTFactors associated with poor response to aflibercept after switching from ranibizumab or bevacizumab in neovascular age-related macular degenerationOphthalmic Surg Lasers Imaging Retina201647545846527183550
   PubMed Web of Science ®Google Scholar
• YangSZhaoJSunXResistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive reviewDrug Des Devel Ther20161018571867
   PubMed Web of Science ®Google Scholar
• EuserAMZoccaliCJagerKJDekkerFWCohort studies: prospective versus retrospectiveNephron Clin Pract20091133c214c21719690438
   PubMedGoogle Scholar
• MenonGChandranMSivaprasadSChavanRNarendranNYangYIs it necessary to use three mandatory loading doses when commencing therapy for neovascular age-related macular degeneration using bevacizumab? (BeMOc Trial)Eye (Lond)201327895996323743535
   PubMed Web of Science ®Google Scholar
• RichardGMonésJWolfSScheduled versus Pro Re Nata Dosing in the VIEW trialsOphthalmology2015122122497250326477840
   PubMed Web of Science ®Google Scholar
• FreundKBEngelbertMFineHFIndividualizing the intravitreal anti-VEGF dosing regimen for long-term management of neovascular AMDOphthalmic Surg Lasers Imaging Retina201546550851226057753
   PubMed Web of Science ®Google Scholar
• Schmidt-ErfurthUKaiserPKKorobelnikJFIntravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studiesOphthalmology2014121119320124084500
   PubMed Web of Science ®Google Scholar
• GasperiniJLFawziAAKhondkaryanABevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularisationBr J Ophthalmol2012961142021791509
   PubMed Web of Science ®Google Scholar
• ForooghianFCukrasCMeyerleCBChewEYWongWTTachyphylaxis after intravitreal bevacizumab for exudative age-related macular degenerationRetina200929672373119516114
   PubMed Web of Science ®Google Scholar
• SchaalSKaplanHJTezelTHIs there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration?Ophthalmology2008115122199220518930553
   PubMed Web of Science ®Google Scholar
• WangWHeMZhangXCombined intravitreal anti-VEGF and photodynamic therapy versus photodynamic monotherapy for polypoidal choroidal vasculopathy: a systematic review and meta-analysis of comparative studiesPLoS One2014910e11066725343244
   PubMed Web of Science ®Google Scholar
• LazzeriSRipandelliGSartiniMSAflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forwardAngiogenesis201518439743226346237
   PubMed Web of Science ®Google Scholar
• Seguin-GreensteinSLightmanSTomkins-NetzerOA meta-analysis of studies evaluating visual and anatomical outcomes in patients with treatment resistant neovascular age-related macular degeneration following switching to treatment with afliberceptJ Ophthalmol20162016409585227042342
   PubMed Web of Science ®Google Scholar
• ZhuMWijeyakumarWSyedARVision-related quality of life: 12-month aflibercept treatment in patients with treatment-resistant neovascular age-related macular degenerationGraefes Arch Clin Exp Ophthalmol Epub2016830
   Web of Science ®Google Scholar